- Home
- WLKP vs GERN Comparison
WLKP vs GERN Comparison
Compare WLKP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- GERN
- Stock Information
- Founded
- WLKP 2014
- GERN 1990
- Country
- WLKP United States
- GERN United States
- Employees
- WLKP N/A
- GERN N/A
- Industry
- WLKP Major Chemicals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- WLKP Industrials
- GERN Health Care
- Exchange
- WLKP Nasdaq
- GERN Nasdaq
- Market Cap
- WLKP 833.7M
- GERN 840.7M
- IPO Year
- WLKP 2014
- GERN 1996
- Fundamental
- Price
- WLKP $23.24
- GERN $1.25
- Analyst Decision
- WLKP
- GERN Buy
- Analyst Count
- WLKP 0
- GERN 9
- Target Price
- WLKP N/A
- GERN $5.13
- AVG Volume (30 Days)
- WLKP 23.2K
- GERN 11.1M
- Earning Date
- WLKP 05-02-2025
- GERN 05-07-2025
- Dividend Yield
- WLKP 8.13%
- GERN N/A
- EPS Growth
- WLKP N/A
- GERN N/A
- EPS
- WLKP 1.49
- GERN N/A
- Revenue
- WLKP $1,088,852,000.00
- GERN $116,293,000.00
- Revenue This Year
- WLKP $8.90
- GERN $194.54
- Revenue Next Year
- WLKP $6.87
- GERN $56.51
- P/E Ratio
- WLKP $15.57
- GERN N/A
- Revenue Growth
- WLKP N/A
- GERN 22264.04
- 52 Week Low
- WLKP $21.19
- GERN $1.17
- 52 Week High
- WLKP $25.04
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- WLKP 49.84
- GERN 39.83
- Support Level
- WLKP $22.80
- GERN $1.25
- Resistance Level
- WLKP $23.42
- GERN $1.44
- Average True Range (ATR)
- WLKP 0.38
- GERN 0.09
- MACD
- WLKP -0.02
- GERN 0.01
- Stochastic Oscillator
- WLKP 52.46
- GERN 19.74
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.